[go: up one dir, main page]

WO2010037130A3 - Compositions and methods of generating reprogrammed adipocyte cells and methods of use therefore - Google Patents

Compositions and methods of generating reprogrammed adipocyte cells and methods of use therefore Download PDF

Info

Publication number
WO2010037130A3
WO2010037130A3 PCT/US2009/058869 US2009058869W WO2010037130A3 WO 2010037130 A3 WO2010037130 A3 WO 2010037130A3 US 2009058869 W US2009058869 W US 2009058869W WO 2010037130 A3 WO2010037130 A3 WO 2010037130A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
adipocyte cells
reprogrammed adipocyte
generating
Prior art date
Application number
PCT/US2009/058869
Other languages
French (fr)
Other versions
WO2010037130A2 (en
Inventor
Joseph P. Vacanti
Howard I. Pryor
David H. Lum
Tim D. Ahfeldt
Chad Cowan
Original Assignee
The General Hospital Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corporation filed Critical The General Hospital Corporation
Publication of WO2010037130A2 publication Critical patent/WO2010037130A2/en
Publication of WO2010037130A3 publication Critical patent/WO2010037130A3/en
Priority to US13/245,716 priority Critical patent/US20120219530A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention provides therapeutic compositions comprising reprogrammed adipocyte cells for use as disease models, therapeutic compositions comprising reprogrammed adipocyte cells for the treatment of conditions characterized by a reduction in cell number or tissue mass, and methods of generating such cells.
PCT/US2009/058869 1999-04-15 2009-09-29 Compositions and methods of generating reprogrammed adipocyte cells and methods of use therefore WO2010037130A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/245,716 US20120219530A1 (en) 1999-04-15 2011-09-26 Compositions and methods of generating reprogrammed adipocyte cells and methods of use therefore

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10094608P 2008-09-29 2008-09-29
US61/100,946 2008-09-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13121401 A-371-Of-International 2009-09-29
US13/245,716 Continuation US20120219530A1 (en) 1999-04-15 2011-09-26 Compositions and methods of generating reprogrammed adipocyte cells and methods of use therefore

Publications (2)

Publication Number Publication Date
WO2010037130A2 WO2010037130A2 (en) 2010-04-01
WO2010037130A3 true WO2010037130A3 (en) 2010-05-27

Family

ID=42060441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/058869 WO2010037130A2 (en) 1999-04-15 2009-09-29 Compositions and methods of generating reprogrammed adipocyte cells and methods of use therefore

Country Status (1)

Country Link
WO (1) WO2010037130A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12251376B2 (en) 2019-02-11 2025-03-18 Servizo Galego De Saúde (Sergas) Combinations with thiazolidinediones for use in the prevention or treatment of abnormal bone growth

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150004144A1 (en) * 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
US10253325B2 (en) 2012-12-19 2019-04-09 Boston Medical Center Corporation Methods for elevating fat/oil content in plants
FR3024462A1 (en) * 2014-07-29 2016-02-05 Univ Pierre Et Marie Curie Paris 6 METHOD FOR IN VITRO PRODUCTION OF ADIPOCYTE PROGENITORS AND ADIPOCYTES
IL320307A (en) * 2022-10-21 2025-06-01 Meatable B V Adipocyte maturation
WO2025141193A1 (en) * 2023-12-29 2025-07-03 Meatable B.V. Adipocyte maturation

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANGHEL ET AL.: "Fat poetry: a kingdom for PPAR gamma.", CELL RES., vol. 17, no. 6, 2007, pages 486 - 511 *
HEGELE.: "Lessons from human mutations in PPARgamma.", INT J OBES (LOND), vol. 29, no. SUP.1, 2005, pages S31 - S35 *
JANDEROVA ET AL.: "Human mesenchymal stem cells as an in vitro model for human adipogenesis.", OBES RES., vol. 11, no. 1, 2003, pages 65 - 74 *
LOWELL.: "PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function.", CELL, vol. 99, no. 3, 1999, pages 239 - 242 *
SANDHU ET AL.: "LDL-cholesterol concentrations: a genome-wide association study.", LANCET, vol. 371, no. 9611, 9 February 2008 (2008-02-09), pages 483 - 491 *
SHOCKLEY ET AL.: "PPARgamma2 Regulates aMolecular Signature of Marrow Mesenchymal Stem Cells.", PPAR RESEARCH., vol. 2007, pages 13, Retrieved from the Internet <URL:http://downloads.hindawi.com/journals/ppar/2007/081219.pdf> [retrieved on 20100327] *
YUN ET AL.: "Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stral3: a mechanism for regulation of adipogenesis by hypoxia.", DEV CELL, vol. 2, no. 3, 2002, pages 331 - 341 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12251376B2 (en) 2019-02-11 2025-03-18 Servizo Galego De Saúde (Sergas) Combinations with thiazolidinediones for use in the prevention or treatment of abnormal bone growth

Also Published As

Publication number Publication date
WO2010037130A2 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
IL260117A (en) Treatment of diseases, disorders or conditions of the lung using placental cells
IL233634A0 (en) Methods, compositions, and kits for the treatment of medical conditions
WO2012048099A3 (en) Nanoparticle-loaded cells
BRPI0912292A2 (en) compositions and methods for the use of cells in the treatment of cardiac tissue.
WO2010111409A3 (en) Pluripotent stem cells
MX2012011543A (en) Treatment of sarcoidosis using placental stem cells.
IL198663A0 (en) Tissue treatment methods
WO2006004910A3 (en) Improved bispecific antibodies
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
PL3135672T3 (en) Compositions and methods for treating alcohol use disorders, pain and other diseases
WO2009114703A3 (en) Combination therapy for the treatment of cancer
WO2009022133A3 (en) Scaffolds
WO2012018643A3 (en) Compositions for proliferation of cells and related methods
IL202257A0 (en) Human umbilical tissue-derived cell compositions for the treatment of incontinence
WO2010014595A3 (en) Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
WO2010037130A3 (en) Compositions and methods of generating reprogrammed adipocyte cells and methods of use therefore
WO2012048170A3 (en) Humanized animals via tissue engineering and uses therefor
EP1948246A4 (en) Stem cell factor therapy for tissue injury
ZA201007005B (en) Methods of diagnosing, preventing and treating bone mass diseases
WO2007025229A3 (en) Compositions and their uses directed to hsp27
WO2011041701A3 (en) Inplantable contrast agents and methods
WO2008011473A3 (en) Compositions and their uses directed to hbxip
WO2012031118A3 (en) Cell permeable inhibitors of anaphase promoting complex
WO2007092319A3 (en) Auditory prosthesis utilizing intra-neural stimulation of the auditory nerve
WO2012051165A3 (en) Mir-211 expression and related pathways in human melanoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09817057

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09817057

Country of ref document: EP

Kind code of ref document: A2